Drug Profile
LFF 269
Alternative Names: LFF269Latest Information Update: 02 Sep 2015
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Essential hypertension
Most Recent Events
- 31 Aug 2013 Novartis initiates enrolment in a phase II trial for Essential hypertension in USA (NCT02047656)
- 10 May 2012 Novartis terminates a phase II trial in Essential hypertension in USA (NCT01373086)